92 studies found for:    coronado
Show Display Options
Rank Status Study
1 Withdrawn TSO for Plaque Psoriasis
Condition: Plaque Psoriasis
Intervention: Biological: Trichuris Suis Ova
2 Active, not recruiting Assess Safety and Efficacy of ELAD (Extracorporeal Liver Assist System) in Subjects With Alcohol-Induced Liver Failure
Condition: Acute Alcoholic Hepatitis
Interventions: Biological: ELAD  treatment;   Other: Standard of care (Control)
3 Unknown  Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
Condition: Crohn's Disease
Interventions: Biological: Trichuris suis ova (TSO);   Biological: Placebo
4 Active, not recruiting Trichuris Suis Ova in Autism Spectrum Disorders
Condition: Autism
Intervention: Drug: Trichuris Suis Ova
5 Terminated Safety and Efficacy of Roflumilast and Pioglitazone in Treating Adults With Nonalcoholic SteatoHepatitis
Condition: Nonalcoholic Steatohapatitis
Interventions: Drug: Roflumilast;   Drug: Pioglitazone;   Drug: Placebo
6 Completed
Has Results
Safety and Tolerability of Single Doses Oral CNDO 201 Trichuris Suis Ova in Patients With Crohn's Disease
Condition: Crohn's Disease
Interventions: Biological: Trichuris suis ova;   Other: Placebo
7 Recruiting Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo in Autism Spectrum Disorder
Condition: Autism
Interventions: Biological: Trichuris suis ova;   Other: Placebo
8 Recruiting CNDO-109-AANK for AML in First Complete Remission (CR1)
Condition: Acute Myeloid Leukemia
Intervention: Biological: CNDO-109-AANK Cells
9 Completed
Has Results
ABT-450 With Ritonavir and ABT-267 and/or ABT-333 With and Without Ribavirin in Genotype 1 Hepatitis C Virus Infected Patients
Conditions: Chronic Hepatitis C;   Hepatitis C (HCV);   Hepatitis C Genotype 1
Interventions: Drug: ABT-450;   Drug: ABT-333;   Drug: ABT-267;   Drug: Ribavirin;   Drug: Ritonavir
10 Completed
Has Results
A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1a Infection
Condition: Chronic Hepatitis C Infection
Interventions: Drug: ABT-450/r/ABT-267;   Drug: ABT-333;   Drug: Ribavirin;   Drug: Placebo for ribavirin
11 Completed Open-Label Study of Sofusbuvir+Ribavirin With or Without Peginterferon Alfa-2a in Subjects With Chronic HCV Infection Who Participated in Prior Gilead HCV Studies
Condition: Chronic Hepatitis C
Interventions: Drug: Sofosbuvir;   Drug: RBV;   Drug: PEG
12 Unknown  Efficacy and Safety Study of PEG-rIL-29 Plus Ribavirin to Treat Chronic Hepatitis C Virus Infection
Condition: Hepatitis C, Chronic
Interventions: Drug: PEG-rIL-29;   Drug: Peginterferon alfa-2a;   Drug: Ribavirin
13 Completed
Has Results
An Efficacy, Safety, and Tolerability Study of TMC435 in Treatment-naive, Genotype 1 Hepatitis C-infected Patients
Condition: Hepatitis C
Interventions: Drug: Placebo;   Drug: TMC435;   Drug: Peginterferon alpha-2a (PegIFN alpha-2a);   Drug: Ribavirin (RBV)
14 Recruiting Efficacy and Safety Study of Cenicriviroc for the Treatment of NASH in Adult Subjects With Liver Fibrosis
Condition: Nonalcoholic Steatohepatitis
Interventions: Drug: Cenicriviroc;   Drug: Placebo
15 Completed Phase 2 Study of NGM282 in Patients With Primary Biliary Cirrhosis
Condition: Primary Biliary Cirrhosis
Interventions: Biological: NGM282;   Biological: Placebo
16 Active, not recruiting Dose-ranging Study of Rifaximin Soluble Solid Dispersion (SSD) Tablets for the Prevention of Complications of Early Decompensated Liver Cirrhosis
Condition: Liver Cirrhosis
Interventions: Drug: Placebo;   Drug: Rifaximin SSD 40 mg IR tablet;   Drug: Rifaximin SSD 80 mg IR tablet;   Drug: Rifaximin SSD 40 mg SER tablet;   Drug: Rifaximin SSD 80 mg SER tablet;   Drug: Rifaximin SSD 80 mg IR tablet + rifaximin SSD 80 mg SER tablet
17 Completed
Has Results
Sofosbuvir + Ribavirin for 12 Weeks in Subjects With Chronic Genotype 2 or 3 Hepatitis C Infection Who Are Interferon Intolerant, Interferon Ineligible or Unwilling to Take Interferon
Condition: Chronic Hepatitis C
Interventions: Drug: SOF;   Drug: RBV;   Drug: Placebo to match SOF;   Drug: Placebo to match RBV
18 Enrolling by invitation A Gilead Sequence Registry of Subjects Who Did Not Achieve Sustained Virologic Response
Condition: Hepatitis C, Chronic
Intervention:
19 Completed GS-5885, GS-9451, Tegobuvir and Ribavirin (RBV) in Interferon Ineligible or Intolerant Subjects With Chronic Genotype 1a or 1b Hepatitis C Virus (HCV) Infection
Condition: Chronic Genotype 1a or 1b HCV Infection
Interventions: Drug: GS-5885 tablet;   Drug: GS-9451 tablet;   Drug: tegobuvir capsule;   Drug: ribavirin tablet;   Drug: placebo matching ribavirin tablet;   Device: placebo matching tegobuvir capsule
20 Enrolling by invitation Gilead Sustained Virologic Response (SVR) Registry
Condition: Hepatitis C, Chronic
Intervention:

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years